Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more
Hebei Changshan Biochem Pharma (300255) - Total Assets
Latest total assets as of September 2025: CN¥4.66 Billion CNY
Based on the latest financial reports, Hebei Changshan Biochem Pharma (300255) holds total assets worth CN¥4.66 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hebei Changshan Biochem Pharma - Total Assets Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hebei Changshan Biochem Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Hebei Changshan Biochem Pharma's total assets of CN¥4.66 Billion consist of 44.3% current assets and 55.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.2% |
| Accounts Receivable | CN¥277.20 Million | 6.1% |
| Inventory | CN¥1.39 Billion | 30.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥735.99 Million | 16.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Hebei Changshan Biochem Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hebei Changshan Biochem Pharma's current assets represent 44.3% of total assets in 2024, a decrease from 61.7% in 2008.
- Cash Position: Cash and equivalents constituted 5.2% of total assets in 2024, up from 0.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 14.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 30.6% of total assets.
Hebei Changshan Biochem Pharma Competitors by Total Assets
Key competitors of Hebei Changshan Biochem Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Hebei Changshan Biochem Pharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hebei Changshan Biochem Pharma generates 0.23x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hebei Changshan Biochem Pharma is currently not profitable relative to its asset base.
Hebei Changshan Biochem Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.87 | 1.13 | 2.12 |
| Quick Ratio | 0.31 | 0.40 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-307.14 Million | CN¥ 266.05 Million | CN¥ 1.59 Billion |
Hebei Changshan Biochem Pharma - Advanced Valuation Insights
This section examines the relationship between Hebei Changshan Biochem Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 41.39 |
| Latest Market Cap to Assets Ratio | 0.68 |
| Asset Growth Rate (YoY) | -1.6% |
| Total Assets | CN¥4.52 Billion |
| Market Capitalization | $3.07 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hebei Changshan Biochem Pharma's assets below their book value (0.68 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hebei Changshan Biochem Pharma's assets decreased by 1.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hebei Changshan Biochem Pharma (2008–2024)
The table below shows the annual total assets of Hebei Changshan Biochem Pharma from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.52 Billion | -1.60% |
| 2023-12-31 | CN¥4.60 Billion | -23.85% |
| 2022-12-31 | CN¥6.04 Billion | +16.30% |
| 2021-12-31 | CN¥5.19 Billion | +13.50% |
| 2020-12-31 | CN¥4.57 Billion | +15.98% |
| 2019-12-31 | CN¥3.94 Billion | +2.54% |
| 2018-12-31 | CN¥3.84 Billion | +8.92% |
| 2017-12-31 | CN¥3.53 Billion | +12.71% |
| 2016-12-31 | CN¥3.13 Billion | +34.52% |
| 2015-12-31 | CN¥2.33 Billion | +13.87% |
| 2014-12-31 | CN¥2.04 Billion | +24.28% |
| 2013-12-31 | CN¥1.65 Billion | +15.99% |
| 2012-12-31 | CN¥1.42 Billion | +19.58% |
| 2011-12-31 | CN¥1.19 Billion | +175.46% |
| 2010-12-31 | CN¥430.64 Million | +61.68% |
| 2009-12-31 | CN¥266.35 Million | +35.48% |
| 2008-12-31 | CN¥196.59 Million | -- |